Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma

Inclusion Criteria: Confirmed Metastatic Melanoma At least 18 years old No other active malignancy Hemoglobin at least 9 Platelet Count at least 100,000 cells/mm3 ANC at least 1500 cells/mm3 AST & ALT less than 2.5X upper limit of normal Total bilirubin less than 1.5mg/dL Creatine less than 1.5 mg/dL Alkaline phosphatase less than 2.5X upper limit of normal Life expectancy of at least 12 weeks ECOG performance status of 0-1 Patient must provide informed consent Patient must provide authorization to disclose Exclusion Criteria: Evidence of active brain metastases The only evidence of metastasis is lytic or blastic bone metastases Pre-existing peripheral neuropathy of NCI Toxicity Criteria Scale of grade greater than 2 Received radiotherapy in last 4wks, except if to a non-target lesion only Clinically significant concurrent illness Investigator's opinion that patient unlikely to complete study Cytotoxic chemotherapeutic agent treatment or investigational drug within previous 4wks History of allergy/hypersensitivity to study drug Serious Medical Risk Factors determine by the investigator